PMID- 25061334
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20140725
LR  - 20211021
IS  - 1178-7074 (Print)
IS  - 1178-7074 (Electronic)
IS  - 1178-7074 (Linking)
VI  - 7
DP  - 2014
TI  - Efficacy and tolerability of carbamazepine for the treatment of painful diabetic 
      neuropathy in adults: a 12-week, open-label, multicenter study.
PG  - 339-43
LID - 10.2147/IJGM.S64419 [doi]
AB  - OBJECTIVE: Anticonvulsants are increasingly being used in the symptomatic 
      management of several neuropathic pain disorders. The present observational study 
      was designed to evaluate the efficacy, tolerability, and quality of life (QoL) of 
      carbamazepine use for 12 weeks in patients with painful diabetic neuropathy, in 
      Pakistan. METHODS: This was a 12-week, multicenter, open-label, uncontrolled 
      trial in adult type 2 diabetic patients (aged 18-65 years) suffering from 
      clinically confirmed neuropathic pain (Douleur Neuropathique en 4 [DN4] score 
      >/=4). Change in neuropathic pain at week 12 compared with baseline was assessed 
      using the Brief Pain Inventory Scale-Short Form (pain severity score and pain 
      interference score). QoL was determined by the American Chronic Pain Association 
      QoL scale. Safety was assessed based on patient reported adverse events (AEs) and 
      serious AEs. RESULTS: Of the total 500 screened patients, 452 enrolled and 
      completed the study. The mean (+/- standard deviation [SD]) pain interference score 
      decreased from 4.5+/-2.0 at baseline to 3.1+/-1.9 at week 12 (P<0.001). The mean (+/- 
      SD) pain severity score decreased from 5.8+/-2.0 at baseline to 3.6+/-2.2 at week 12 
      (P<0.001). There was a decrease of >/=30% in the pain severity score between 
      visits. The mean (+/- SD) QoL scale score improved from 5.9+/-1.6 at baseline to 
      8.0+/-1.7 at week 12. A total of ten (2.2%) patients reported AEs during the study 
      period. No patient discontinued the study due to AEs. CONCLUSION: In this 
      real-life experience study, carbamazepine, when prescribed for 12 weeks to adult 
      diabetic patients suffering from neuropathic pain, showed pain-relief effect, 
      with reduced mean pain severity and mean pain interference scores and with 
      improved QoL and good tolerability profile.
FAU - Saeed, Tariq
AU  - Saeed T
AD  - Pakistan Telecommunication Company Ltd, Karachi, Pakistan.
FAU - Nasrullah, Muhammad
AU  - Nasrullah M
AD  - Cavalary Hospital, Gulberg, Lahore, Pakistan.
FAU - Ghafoor, Adnan
AU  - Ghafoor A
AD  - Fauji Foundation Hospital, Rawalpindi, Pakistan.
FAU - Shahid, Riaz
AU  - Shahid R
AD  - Dr Riaz Shahid Clinic, Peshawar Cantt, Peshawar, Pakistan.
FAU - Islam, Nadeem
AU  - Islam N
AD  - Punjab Employs Social Security Institution, Islamabad, Pakistan.
FAU - Khattak, Mohammad Usman
AU  - Khattak MU
AD  - Medical B Unit, Hayat Abad Medical Complex, Peshawar, Pakistan.
FAU - Maheshwary, Neeta
AU  - Maheshwary N
AD  - Novartis Pharma Pakistan, Karachi, Pakistan.
FAU - Siddiqi, Ahson
AU  - Siddiqi A
AD  - Novartis Pharma Pakistan, Karachi, Pakistan.
FAU - Khan, Muhammad Athar
AU  - Khan MA
AD  - Department of Medical Education, King Saud bin Abdulaziz University, Riyadh, 
      Kingdom of Saudi Arabia.
LA  - eng
PT  - Journal Article
DEP - 20140702
PL  - New Zealand
TA  - Int J Gen Med
JT  - International journal of general medicine
JID - 101515487
PMC - PMC4085303
OTO - NOTNLM
OT  - anticonvulsant
OT  - neuropathic pain
OT  - quality of life
EDAT- 2014/07/26 06:00
MHDA- 2014/07/26 06:01
PMCR- 2014/07/02
CRDT- 2014/07/26 06:00
PHST- 2014/07/26 06:00 [entrez]
PHST- 2014/07/26 06:00 [pubmed]
PHST- 2014/07/26 06:01 [medline]
PHST- 2014/07/02 00:00 [pmc-release]
AID - ijgm-7-339 [pii]
AID - 10.2147/IJGM.S64419 [doi]
PST - epublish
SO  - Int J Gen Med. 2014 Jul 2;7:339-43. doi: 10.2147/IJGM.S64419. eCollection 2014.